SC Mosunetuzumab Exhibits Response Durability in Follicular LymphomaByEmmanuel Bachy, MD, PhDJune 14th 2026Emmanuel Bachy, MD, PhD, highlighted high efficacy, durable responses, and a favorable adverse effect profile in follicular lymphoma with high tumor burden.